Evidence for a complex interaction between the subtypes of the alpha 1-adrenoceptor.
Ligand binding studies with WB 4101 revealed that the rat aorta contains both the alpha 1a- and alpha 1b-adrenoceptor subtypes. Results obtained following treatment with the irreversible antagonists phenoxybenzamine, chlorethylclonidine or SZL-49 (4-amino-6,7-dimethoxy-2-quinazolinyl-4-(2-bicyclo[2,2,2]octa-2,5- dienylcarbonyl-2-piperazine) suggest that there is a complex interaction between the alpha 1-adrenoceptor subtypes in the aorta. Chlorethylclonidine affects only the alpha 1b-adrenoceptor, whereas the predominant action of SZL-49 is on the alpha 1a-subtype. Chlorethylclonidine significantly inhibited the response to either methoxamine or phenylephrine, agents which are selective alpha 1a-adrenoceptor agonists. Following inactivation with either chlorethylclonidine or SZL-49, the response of the rat aorta to phenylephrine was only partially antagonized by either prazosin or WB 4101. SZL-49 also inhibited the response of the rat tail artery to electrical stimulation. The response of the tail artery obtained following inactivation with SZL-49 was effectively antagonized by prazosin. Phenylephrine, prazosin or WB 4101 afforded complete protection from chlorethylclonidine adrenoceptor inactivation, while these same ligands were only partially effective against SZL-49. Either SZL-49 or chlorethylclonidine significantly impaired the irreversible adrenoceptor blocking actions of phenoxybenzamine. These results suggest: (1) only the alpha 1a-adrenoceptor subtype appears to be associated with nerve terminals in the tail artery, (2) there may be a complex interaction between the alpha 1-adrenoceptor subtypes such that both receptors must be intact and functional to observe normal agonist and antagonist interactions, (3) there may be three sites of action for agonists associated with the rat aorta.
Department of Pharmacology, College of Medicine, University of Kentucky, Lexington 40536.
M T
MT
Piascik
M S
MS
Sparks
T A
TA
Pruitt
E E
EE
Soltis
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001013:Aorta, Thoracic / Q000378:metabolism; D001667:Binding, Competitive; D003000:Clonidine / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004146:Dioxanes / Q000378:metabolism; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D008729:Methoxamine / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000502:physiology / Q000648:ultrastructure; D010643:Phenoxybenzamine / Q000494:pharmacology; D010656:Phenylephrine / Q000037:antagonists & inhibitors; D011224:Prazosin / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000145:classification / Q000502:physiology*
D000317:Adrenergic alpha-Antagonists; D004146:Dioxanes; D011942:Receptors, Adrenergic, alpha; D010643:Phenoxybenzamine; C051307:SZL 49; D010656:Phenylephrine; C051731:chlorethylclonidine; C010654:(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane; D008729:Methoxamine; D003000:Clonidine; D011224:Prazosin